Skip to main content
    E

    Entero Therapeutics, Inc. (ENTO)

    Official site

    BIOTECHNOLOGY

    $3.74
    -1.68 (-31.00%)

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Entero Therapeutics, Inc. (ENTO) Financials: Revenue, Profit and Cash Flow

    Updated Mar 31, 2026. Financial statements from company filings, amounts in US dollars.

    Entero Therapeutics reported revenue of $36.25K for the fiscal year ended Dec 31, 2025. That year, net income was -$6.55M with a net margin of -18078.3% and operating cash flow was -$5.70M. The quarter ended Mar 31, 2026 had revenue of $38.21K and net income of -$3.44M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$36.25KN/A-1813.6%-19540.0%-18078.3%
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$36.25K$0$0$0$0$0$0$0$0$0
    Cost of revenue$693.68K$0$0$0$0$0$0$0$0$0
    Gross profit-$657.43K$0$0$0$0$0$0$0$0$0
    Research and development$925.48K$903.94K$5.03M$691.26K$38.32M$19.14M$8.68M$5.77M$2.40M$2.50M
    Operating income-$7.08M-$15.62M-$15.77M-$12.68M-$59.06M-$26.43M-$14.74M-$13.43M-$10.22M-$6.33M
    Net income-$6.55M-$18.06M-$15.79M-$14.63M-$58.54M-$32.67M-$15.18M-$13.53M-$11.10M-$14.59M
    EBITDA-$5.21M-$15.57M-$15.75MN/A-$57.99M-$25.66M-$14.16M-$12.63MN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue$38.21K$36.25K$0$0$0$0$0$0$0$0$0$0
    Gross profit-$613.74K-$657.43K$0$0$0N/A$0$0$0-$7.32K$0$0
    Operating income-$3.61M-$4.69M-$934.79K-$638.86K-$821.39K-$1.20M-$1.89M-$3.43M-$9.10M-$4.09M-$3.43M-$4.18M
    Net income-$3.44M-$3.14M-$1.15M-$998.27K-$1.26M-$12.24M-$2.58M-$8.81M$5.57M-$4.10M-$3.43M-$4.19M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $8.28M exceeded cash and equivalents by $7.38M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$48.55M$85.41M$6.88M$5.44M$11.79M$12.92M$8.90M$7.47M$5.48M$6.75M
    Current assets$2.60M$83.48M$4.96M$3.41M$9.42M$7.87M$3.41M$4.80M$1.95M$2.96M
    Cash and equivalents$899.78K$163.48K$3.71M$1.36M$8.25M$6.06M$175.80K$1.11M$573.47K$1.77M
    Total liabilities$19.72M$27.61M$3.28M$2.70M$19.61M$15.56M$4.29M$3.00M$3.82M$3.54M
    Short-term debt$8.28M$0$612.78K$603.49K$641.24K$552.40K$1.52M$255.03K$416.55K$155.19K
    Shareholder equity$19.82M-$3.88M$3.60M$2.74M-$7.82M-$2.64M$4.62M$4.47M$1.66M$3.21M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$47.97M$48.55M$135.37M$85.06M$85.20M$85.41M$85.82M$86.29M$91.13M$6.88M$5.93M$4.33M
    Total liabilities$20.47M$19.72M$45.81M$29.68M$28.74M$27.61M$15.77M$15.49M$13.27M$3.28M$2.65M$3.45M
    Cash and equivalents$385.54K$899.78K$2.52M$4.47K$59.35K$163.48K$366.79K$662.48K$3.43M$3.71M$3.29M$1.24M
    Shareholder equity$18.59M$19.82M$22.59M-$6.30M-$5.22M$57.80M$8.37M$9.12M$16.18M$3.60M$3.28M$881.96K
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$5.70M-$9.22M-$12.38M-$22.34M-$32.29M-$11.22M-$14.03M-$10.87M-$7.18M-$4.53M
    Capital expendituresN/A$0$500.00K$0$69.49K$4.17K$24.10K$305.47K$32.17K$12.36K
    Free cash flowN/A-$9.22M-$12.88M-$22.34M-$32.36M-$11.23M-$14.06M-$11.17M-$7.22M-$4.55M
    Share repurchasesN/AN/AN/AN/AN/AN/AN/AN/AN/A$1.42M
    Investing cash flow$323.48K$88.17K-$500.00K$0-$10.32M$87.35K-$24.10K-$305.47K-$32.17K-$12.36K
    Financing cash flow$5.89M$5.58M$15.23M$15.74M$44.76M$17.05M$13.14M$11.71M$6.01M$5.75M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-$1.79M-$3.97M-$855.69K-$54.88K-$818.63K-$171.52K-$1.85M-$3.45M-$3.75M-$3.44M-$3.33M-$2.76M
    Capital expendituresN/AN/A$0$0$0$0$0$0$4$500.00K$0$0
    Free cash flowN/AN/A-$855.69K-$54.88K-$818.63K-$171.52K-$1.85M-$3.45M-$3.75M-$3.94M-$3.33M-$2.76M
    Last 12 quarters

    Frequently Asked Questions About ENTO

    What is Entero Therapeutics' annual revenue?

    Entero Therapeutics reported revenue of $36.25K for the fiscal year ended Dec 31, 2025.

    Is Entero Therapeutics profitable?

    No. Entero Therapeutics reported net income of -$6.55M for the fiscal year ended Dec 31, 2025, with a net margin of -18078.3%.

    How much debt does Entero Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $8.28M and cash and equivalents of $899.78K.

    What is ENTO's profit margin?

    For the fiscal year ended Dec 31, 2025, Entero Therapeutics reported gross margin of -1813.6%, operating margin of -19540.0% and net margin of -18078.3%.